Listen to this story. Enjoy more audio and podcasts on iOS or Android.
Your browser does not support the element.
FIVE YEARS ago Novo Nordisk was a boring Danish drugmaker whose diabetes medications were reliably profitable. The only time the company made headlines was when it was caught up in complaints about the high cost of insulin. Then in 2021 a trial of its diabetes drug, Ozempic (semaglutide), showed that people taking it lost weight. A great deal of weight—up to 15% of their body mass. Excitement about the drug has kept Novo Nordisk in the headlines. Its market value has nearly quadrupled
→ Continue reading at The Economist
